Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients
Primary Purpose
Cardiovascular Diseases, Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Vitamin K2 (menaquinone-7; 360-mcg/d)
Placebo-Control
Sponsored by
About this trial
This is an interventional prevention trial for Cardiovascular Diseases focused on measuring Arterial Stiffness, Endothelial Function, Vitamin K
Eligibility Criteria
Inclusion Criteria:
- Chronic Kidney Disease Stages 3 to 5
- Receiving hemodialysis treatment for at least 3 months
- Subject understands the study protocol and agrees to comply with it
- Informed consent documents signed by subject
Exclusion Criteria:
- Using vitamin supplements containing vitamin K
- History of metabolic gastrointestinal diseases
- Subjects presenting chronic degenerative and/or inflammatory diseases
- Receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters (salicylates, antibiotics)
- Subjects receiving corticosteroid
- Use of anticoagulants
- History of soy allergy
- Have an unstable medical condition, such as having a life expectancy of less than 6 months in the judgment of the investigator
- Known sensitivity, intolerance, or other adverse response to study drugs which would prevent compliance with study medication
- Subjects who have participated in a clinical study more recently than one month before the current study
Sites / Locations
- Augusta UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Placebo-Control
Vitamin K2 (360-mcg/d)
Arm Description
The placebo-control group will take four placebo softgel capsules (similar in taste and appearance to the vitamin K2 supplements) every day for 8 weeks.
The experimental group will take four 90-mcg of vitamin K2 (menaquinone-7; 360-mcg) softgel capsules every day for 8 weeks.
Outcomes
Primary Outcome Measures
Flow-Mediated Dilation (FMD)
The FMD test is non-invasive assessment of vascular endothelial function.
Pulse Wave Velocity (PWV)
The PWV test is a non-invasive test of arterial stiffness.
Secondary Outcome Measures
Prothrombin Time
The prothrombin time test is a measurement of clotting time.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03311321
Brief Title
Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients
Official Title
Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients (Vita-K 'n' CKD Study)
Study Type
Interventional
2. Study Status
Record Verification Date
November 2019
Overall Recruitment Status
Unknown status
Study Start Date
September 13, 2017 (Actual)
Primary Completion Date
December 1, 2021 (Anticipated)
Study Completion Date
December 30, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Augusta University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The life span of adults with end-stage renal disease is reduced, and cardiovascular disease (CVD) accounts for approximately half the deaths among those undergoing hemodialysis (HD). Vascular calcification is a key process in the development of atherosclerotic and arteriosclerotic CVD, and contributes significantly to the greater mortality rates and CVD events in HD patients. Recently, there has been growing interest in the vitamin K-dependent matrix Gla protein (MGP) and its role in inhibiting vascular calcification. Animal studies have revealed that the vitamin K-dependent protein MGP may reduce the progression of vascular calcification, possibly by means of improving vascular function. The relationship between MGP and vitamin K lies in the fact that inactive matrix Gla protein requires vitamin K to carboxylate it for its activation. Currently, data in HD patients are scant and equivocal on the effects of vitamin K supplementation on CVD risk outcomes. Therefore, the purpose of this 8-week randomized, placebo-controlled, double-blind clinical trial is to determine whether daily vitamin K supplementation can favorably alter measurements of endothelial function and arterial stiffness in HD patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiovascular Diseases, Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5, Vitamin K Deficiency, Hemodialysis
Keywords
Arterial Stiffness, Endothelial Function, Vitamin K
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Placebo-Control
Arm Type
Placebo Comparator
Arm Description
The placebo-control group will take four placebo softgel capsules (similar in taste and appearance to the vitamin K2 supplements) every day for 8 weeks.
Arm Title
Vitamin K2 (360-mcg/d)
Arm Type
Experimental
Arm Description
The experimental group will take four 90-mcg of vitamin K2 (menaquinone-7; 360-mcg) softgel capsules every day for 8 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin K2 (menaquinone-7; 360-mcg/d)
Intervention Description
four 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo-Control
Intervention Description
four placebo softgel capsules per day for 8 weeks containing no vitamin K2 (menaquinone-7)
Primary Outcome Measure Information:
Title
Flow-Mediated Dilation (FMD)
Description
The FMD test is non-invasive assessment of vascular endothelial function.
Time Frame
Change from baseline to 8 weeks
Title
Pulse Wave Velocity (PWV)
Description
The PWV test is a non-invasive test of arterial stiffness.
Time Frame
Change from baseline to 8 weeks
Secondary Outcome Measure Information:
Title
Prothrombin Time
Description
The prothrombin time test is a measurement of clotting time.
Time Frame
Change from baseline to 8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Chronic Kidney Disease Stages 3 to 5
Receiving hemodialysis treatment for at least 3 months
Subject understands the study protocol and agrees to comply with it
Informed consent documents signed by subject
Exclusion Criteria:
Using vitamin supplements containing vitamin K
History of metabolic gastrointestinal diseases
Subjects presenting chronic degenerative and/or inflammatory diseases
Receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters (salicylates, antibiotics)
Subjects receiving corticosteroid
Use of anticoagulants
History of soy allergy
Have an unstable medical condition, such as having a life expectancy of less than 6 months in the judgment of the investigator
Known sensitivity, intolerance, or other adverse response to study drugs which would prevent compliance with study medication
Subjects who have participated in a clinical study more recently than one month before the current study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Norman K Pollock, PhD
Phone
706-721-4524
Email
npollock@augusta.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Celestine Williams, MS
Phone
706-721-8553
Email
cewilliams@augusta.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Norman K Pollock, PhD
Organizational Affiliation
Augusta University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Augusta University
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30901
Country
United States
Individual Site Status
Recruiting
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Approximate date of when the data will be shared? 2019-06-01
Where will the data be made available? The de-identified data will be made available for research purposes only by contacting the principal investigator.
Please explain any limits to data sharing that might be required. Even though the final research data will be stripped of identifiers prior to release for sharing, the investigators believe that there remains the possibility of deductive disclosure of subjects with unusual characteristics. Thus, the principal investigator will make the data available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.
IPD Sharing Time Frame
The data will become available on June 1, 2019 for approximately 12 months.
IPD Sharing Access Criteria
The principal investigator will make the data available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.
IPD Sharing URL
http://www.augusta.edu/mcg/dphs/gpi/clinicalresearch.php
Citations:
PubMed Identifier
29635270
Citation
Fain ME, Kapuku GK, Paulson WD, Williams CF, Raed A, Dong Y, Knapen MHJ, Vermeer C, Pollock NK. Inactive Matrix Gla Protein, Arterial Stiffness, and Endothelial Function in African American Hemodialysis Patients. Am J Hypertens. 2018 May 7;31(6):735-741. doi: 10.1093/ajh/hpy049.
Results Reference
background
Links:
URL
https://www.augusta.edu/faculty/directory/view.php?id=NPOLLOCK
Description
Principal Investigator - Faculty Profile
Learn more about this trial
Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients
We'll reach out to this number within 24 hrs